Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss
Status:
Withdrawn
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
Recurrent pregnancy loss (RPL) affects 5% of couples trying to achieve parenthood. Most cases
of RPL are unexplained and have no effective treatment to improve the likelihood of a
pregnancy resulting in a live birth. This leads to significant patient and provider
frustration and emotional stress. Hydroxychloroquine (HCQ) is a medication commonly used in
pregnancy to treat autoimmune and connective tissue diseases such as systemic lupus
erythematosus (SLE). This use has shown that HCQ is very safe in pregnancy. HCQ has
anti-inflammatory and anti-thrombotic effects and thus may improve pregnancy outcomes in
couples with unexplained RPL. Although some providers are already prescribing HCQ for
unexplained RPL, a randomized controlled trial is necessary to determine the true efficacy
and safety of this treatment. This study has the potential to establish support for a new
treatment option for unexplained RPL.